Please assess the completion status of the following clinical trial:

Trial Title: Seizure Prophylaxis in Patients With Glioma or Brain Metastasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with a suspected diagnosis of new, recurrent, or transformed glioma (WHO grade I-IV) or brain metastasis scheduled for neurosurgical procedure (gross-total resection, sub-total resection or biopsy) at Duke University Medical Center (DUMC);~2. Safe for surgery per treating neurosurgeon;~3. Due to the potential implications of the treatment on the developing central nervous system (CNS), all patients must be ≥ 18 years of age at the time of entry into the study;~4. Laboratory Studies:~   1. Total bilirubin, Serum Glutamic Oxaloacetic Transaminase (SGOT), Serum Glutamic Pyruvic Transaminase (SGPT), Alkaline Phosphatase (ALK) ≤ 1.5 x upper limit of normal (ULN)~  2. Creatinine ≤ 1.5~5. A signed informed consent form approved by the Duke University Institutional Review Board (IRB) will be required for patient enrollment into the study. Patients must be able to read and understand the informed consent document and must sign the informed consent indicating that they are aware of the investigational nature of this study.~6. Patients of child bearing potential or with partners of child-bearing potential must agree to practice recommended contraceptive methods to prevent pregnancy during treatment and for 1 month after the last dose of AED for women and men.~Exclusion Criteria:~1. Pregnant or need to breast feed during the study period (Negative urine β-human chorionic gonadotropin (HCG) test required), or unable to maintain use of contraception while on study and for 1 month after the last dose of AED;~2. Patients already on AED(s);~3. Known history of epilepsy/seizure disorder;~4. Known history of dependency/abuse of psychopharmaceuticals, alcohol, illicit drugs or narcotics;~5. Any significant medical or psychiatric illness that cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate therapy, per the discretion of the treating investigator;~6. Known allergy to LCM or LEV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Lacosamide (Type: ACTIVE_COMPARATOR): Enrolled subjects will be randomized to receive Lacosamide.
- Levetiracetam (Type: ACTIVE_COMPARATOR): Enrolled subjects will be randomized to receive Levetiracetam.
- No anti-epileptic (Type: NO_INTERVENTION): Enrolled subjects will be randomized to not receive anti-epileptic drugs.

Based on this trial design, predict the completion outcome and termination type (if applicable).